No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration of tenofovir-DF (300 mg), emtricitabine (200 mg) with efavirenz (once daily) and sofosbuvir (400 mg single dose) was studied in 16 subjects. Sofosbuvir Cmax decreased by 19% and there was no change in AUC; GS-331007 (metabolite of sofosbuvir) Cmax decreased by 23%, with no change in AUC. Tenofovir Cmax increased by 25%, but there was no change in AUC and Cmin. There was no change in emtricitabine AUC, Cmax or Cmin. No dose adjustment is required.
Coadministration of sofosbuvir (400 mg once daily) and emtricitabine/tenofovir disoproxil fumarate (200/300 mg once daily with efavirenz (600 mg once daily) had no effect on sofosbuvir AUC but decreased Cmax by 19%. There was no effect on GS-331007 (the prominent circulating metabolite of sofosbuvir) AUC but Cmax decreased by 23%. There was no change in the AUC, Cmax and Cmin of efavirenz or emtricitabine. Tenofovir AUC and Cmin were unaltered, but Cmin increased by 25%. No dose adjustment is required.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
No clinically significant drug interactions have been observed between TDF and sofosbuvir. Coadministration of sofosbuvir (400 mg single dose) and tenofovir-DF (300 mg once daily) in the presence of efavirenz increased tenofovir Cmax by 25%, but there was no change in AUC or Cmin (n=16).
Truvada US Prescribing Information, Gilead Sciences Inc, May 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking